[go: up one dir, main page]

WO2021202669A3 - Composés conjugués de nucléoside et de nucléotide et leurs utilisations - Google Patents

Composés conjugués de nucléoside et de nucléotide et leurs utilisations Download PDF

Info

Publication number
WO2021202669A3
WO2021202669A3 PCT/US2021/025095 US2021025095W WO2021202669A3 WO 2021202669 A3 WO2021202669 A3 WO 2021202669A3 US 2021025095 W US2021025095 W US 2021025095W WO 2021202669 A3 WO2021202669 A3 WO 2021202669A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
nucleoside
nucleotide conjugate
conjugate compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/025095
Other languages
English (en)
Other versions
WO2021202669A2 (fr
Inventor
Frank Shujie HOU
Jian XUE
Yushan ZHAO
Dezu MIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reyoung Drug Discovery Co Ltd
Reyoung Corp
Original Assignee
Reyoung Drug Discovery Co Ltd
Reyoung Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reyoung Drug Discovery Co Ltd, Reyoung Corp filed Critical Reyoung Drug Discovery Co Ltd
Publication of WO2021202669A2 publication Critical patent/WO2021202669A2/fr
Publication of WO2021202669A3 publication Critical patent/WO2021202669A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des composés conjugués de nucléoside et de nucléotide, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés et des procédés d'utilisation de tels composés dans le traitement d'états, de maladies ou de troubles, tels que des infections virales et des cancers.
PCT/US2021/025095 2020-04-01 2021-03-31 Composés conjugués de nucléoside et de nucléotide et leurs utilisations Ceased WO2021202669A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003645P 2020-04-01 2020-04-01
US63/003,645 2020-04-01

Publications (2)

Publication Number Publication Date
WO2021202669A2 WO2021202669A2 (fr) 2021-10-07
WO2021202669A3 true WO2021202669A3 (fr) 2021-12-02

Family

ID=75625662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025095 Ceased WO2021202669A2 (fr) 2020-04-01 2021-03-31 Composés conjugués de nucléoside et de nucléotide et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2021202669A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4594520A2 (fr) 2022-09-30 2025-08-06 Sixfold Bioscience Ltd. Compositions contenant des oligonucléotides ayant des applications théranostiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066189A1 (fr) * 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates pour traiter des maladies virales
EP2860185A1 (fr) * 2013-10-09 2015-04-15 Zentiva, k.s. Procédé amélioré pour la préparation du Ténofovir disoproxil et ses sels pharmaceutiquement acceptables
CN102850402B (zh) * 2011-06-28 2016-08-03 李勤耕 非环核苷环状磷酸酯类衍生物，其制备方法及医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
KR101236669B1 (ko) 2004-07-21 2013-02-22 길리어드 파마셋 엘엘씨 알킬-치환된 2-데옥시-2-플루오로-ｄ-리보퓨라노실피리미딘 및 퓨린 및 그 유도체의 제조
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AP3237A (en) 2008-04-23 2015-04-30 Gilead Sciences Inc 1'-Substituted carba-nucleoside analogs for antiviral treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066189A1 (fr) * 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates pour traiter des maladies virales
CN102850402B (zh) * 2011-06-28 2016-08-03 李勤耕 非环核苷环状磷酸酯类衍生物，其制备方法及医药用途
EP2860185A1 (fr) * 2013-10-09 2015-04-15 Zentiva, k.s. Procédé amélioré pour la préparation du Ténofovir disoproxil et ses sels pharmaceutiquement acceptables

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUBER Y: "Synthesis and anti-HIV-1 integrase activity of modified dinucleotides", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 1 January 2009 (2009-01-01), pages 5029 - 5044, XP055826603 *
AUBERT Y ET AL: "Synthesis and anti-HIV-1 integrase activity of modified dinucleotides", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 12, 1 December 2009 (2009-12-01), pages 5029 - 5044, XP026776617, ISSN: 0223-5234, [retrieved on 20090909], DOI: 10.1016/J.EJMECH.2009.09.007 *

Also Published As

Publication number Publication date
WO2021202669A2 (fr) 2021-10-07

Similar Documents

Publication Publication Date Title
WO2021262826A3 (fr) Analogues de 1'-cyano nucléoside et leurs utilisations
WO2004041203A3 (fr) Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations
EP4566675A3 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
WO2020160193A3 (fr) Composés et leurs utilisations
JO2755B1 (en) (Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection)
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CR20230164A (es) Compuestos fosfolípidos y usos de estos
EP4596543A3 (fr) Agonistes du récepteur farnésoïde x et leursutilisations
MY144616A (en) Substituted dihydroquinazolines
EP4537828A3 (fr) Composés phospholipidiques et leurs utilisations
EP4252755A3 (fr) Composés thérapeutiques
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2021262910A3 (fr) Tubulysines et conjugués tubulysines-protéines
WO2022175746A8 (fr) Inhibiteurs de tyk2 et leurs utilisations
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2021013602A (es) Inhibidores de jak.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MX2022011576A (es) Moduladores de nlrp3.
MX2024006064A (es) Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
WO2024099364A3 (fr) Composés multicycliques fusionnés et leur utilisation en tant qu'inhibiteurs de parp1
AU2020210930B2 (en) GPR35 modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21720632

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21720632

Country of ref document: EP

Kind code of ref document: A2